Parkman Healthcare Partners 13F annual report
Parkman Healthcare Partners is an investment fund managing more than $734 billion ran by Michael Elgort. There are currently 89 companies in Mr. Elgort’s portfolio. The largest investments include Boston Scientific and Insulet, together worth $78.7 billion.
$734 billion Assets Under Management (AUM)
As of 7th August 2024, Parkman Healthcare Partners’s top holding is 551,592 shares of Boston Scientific currently worth over $42.5 billion and making up 5.8% of the portfolio value.
Relative to the number of outstanding shares of Boston Scientific, Parkman Healthcare Partners owns more than approximately 0.1% of the company.
In addition, the fund holds 179,305 shares of Insulet worth $36.2 billion, whose value grew 3.1% in the past six months.
The third-largest holding is United Therapeutics Corp worth $35.5 billion and the next is Eli Lilly & Co worth $28.7 billion, with 31,654 shares owned.
Currently, Parkman Healthcare Partners's portfolio is worth at least $734 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Parkman Healthcare Partners
The Parkman Healthcare Partners office and employees reside in Stamford, Connecticut. According to the last 13-F report filed with the SEC, Michael Elgort serves as the CHIEF FINANCIAL OFFICER / CHIEF COMPLIANCE OFFICER at Parkman Healthcare Partners.
Recent trades
In the most recent 13F filing, Parkman Healthcare Partners revealed that it had opened a new position in
Cooper Cos Inc and bought 308,398 shares worth $26.9 billion.
The investment fund also strengthened its position in Boston Scientific by buying
123,361 additional shares.
This makes their stake in Boston Scientific total 551,592 shares worth $42.5 billion.
Boston Scientific soared 47.9% in the past year.
On the other hand, there are companies that Parkman Healthcare Partners is getting rid of from its portfolio.
Parkman Healthcare Partners closed its position in Cooper Cos Inc on 14th August 2024.
It sold the previously owned 52,384 shares for $19.6 billion.
Michael Elgort also disclosed a decreased stake in Tenet Healthcare by 0.2%.
This leaves the value of the investment at $19.8 billion and 148,927 shares.
One of the average hedge funds
The two most similar investment funds to Parkman Healthcare Partners are Cutler Investment Counsel and Gamma Investing. They manage $734 billion and $734 billion respectively.
Michael Elgort investment strategy
Parkman Healthcare Partners’s portfolio is diversified across 3 sectors.
Currently, their heaviest sector is Health Care — making up 66.0% of
the total portfolio value.
The fund focuses on investments in the United States as
52.8% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
12% of the total holdings value.
On the other hand, small-cap stocks make up only 5.6% of the portfolio.
The average market cap of the portfolio companies is close to $11.1 billion.
The complete list of Parkman Healthcare Partners trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Boston Scientific Corp. |
28.81%
551,592
|
$42,478,100,000 | 5.79% |
| Insulet Corporation |
523.80%
179,305
|
$36,183,749,000 | 4.93% |
| United Therapeutics Corp |
3.06%
111,381
|
$35,480,418,000 | 4.83% |
| Eli Lilly & Co |
14.39%
31,654
|
$28,658,899,000 | 3.90% |
| Cooper Cos Inc |
Opened
308,398
|
$26,923,145,000 | 3.67% |
| Tenet Healthcare Corp. |
19.86%
148,927
|
$19,811,759,000 | 2.70% |
| Cooper Cos Inc |
Closed
52,384
|
$19,558,090,000 | |
| Agios Pharmaceuticals Inc |
Opened
446,416
|
$19,249,458,000 | 2.62% |
| Longboard Pharmaceuticals In |
Opened
694,178
|
$18,763,631,000 | 2.56% |
| Rxsight Inc |
30.63%
296,739
|
$17,854,786,000 | 2.43% |
| Dexcom Inc |
98.73%
156,855
|
$17,784,220,000 | 2.42% |
| Becton Dickinson & Co. |
71.33%
68,167
|
$15,931,310,000 | 2.17% |
| Neurocrine Biosciences, Inc. |
47.13%
115,170
|
$15,855,454,000 | 2.16% |
| Lantheus Holdings Inc |
Closed
187,187
|
$15,454,159,000 | |
| Elevance Health Inc |
28.22%
27,751
|
$15,037,157,000 | 2.05% |
| Seagen Inc |
Closed
73,100
|
$14,800,557,000 | |
| Schrodinger, Inc. |
80.72%
721,373
|
$13,951,354,000 | 1.90% |
| Intra-Cellular Therapies Inc |
Opened
185,028
|
$12,672,568,000 | 1.73% |
| Abbott Labs |
Opened
121,913
|
$12,667,980,000 | 1.73% |
| Mannkind Corp |
63.46%
2,409,599
|
$12,578,107,000 | 1.71% |
| Day One Biopharmaceuticals I |
127.08%
908,822
|
$12,523,567,000 | 1.71% |
| Syndax Pharmaceuticals Inc |
Opened
600,698
|
$12,332,330,000 | 1.68% |
| Kiniksa Pharmaceuticals Intl |
Opened
647,142
|
$12,082,141,000 | 1.65% |
| Icon Plc |
Opened
37,056
|
$11,615,944,000 | 1.58% |
| Vaxcyte, Inc. |
19.29%
150,191
|
$11,340,922,000 | 1.54% |
| Humana Inc. |
68.40%
30,037
|
$11,223,325,000 | 1.53% |
| Bicycle Therapeutics plc |
262.02%
535,063
|
$10,829,675,000 | 1.48% |
| Edgewise Therapeutics Inc |
822.43%
574,517
|
$10,347,051,000 | 1.41% |
| Shockwave Med Inc |
Closed
46,855
|
$10,159,570,000 | |
| Nurix Therapeutics, Inc. |
Opened
474,679
|
$9,906,551,000 | 1.35% |
| Qiagen NV |
Opened
234,267
|
$9,626,031,000 | 1.31% |
| Inari Med Inc |
Opened
195,567
|
$9,416,551,000 | 1.28% |
| Silk Rd Med Inc |
Closed
239,864
|
$9,385,878,000 | |
| IQVIA Holdings Inc |
Closed
45,643
|
$9,077,936,000 | |
| Keros Therapeutics, Inc. |
10.79%
198,627
|
$9,077,254,000 | 1.24% |
| Alphatec Holdings Inc |
Opened
852,416
|
$8,907,747,000 | 1.21% |
| Arcellx Inc |
6.23%
156,843
|
$8,656,165,000 | 1.18% |
| Verona Pharma Plc |
22.01%
595,389
|
$8,609,325,000 | 1.17% |
| Gilead Sciences, Inc. |
Opened
125,000
|
$8,576,250,000 | 1.17% |
| Cencora Inc. |
Opened
38,014
|
$8,564,554,000 | 1.17% |
| Zimmer Biomet Holdings Inc |
Closed
65,000
|
$8,398,000,000 | |
| Bristol-Myers Squibb Co. |
Opened
200,000
|
$8,306,000,000 | 1.13% |
| Xenon Pharmaceuticals Inc |
24.52%
209,290
|
$8,160,217,000 | 1.11% |
| Travere Therapeutics Inc |
583.57%
969,892
|
$7,972,512,000 | 1.09% |
| Ionis Pharmaceuticals Inc |
6.98%
161,705
|
$7,706,860,000 | 1.05% |
| Deciphera Pharmaceuticals In |
Closed
491,772
|
$7,597,877,000 | |
| CTI BioPharma Corp |
Closed
1,753,630
|
$7,365,246,000 | |
| Karuna Therapeutics Inc |
Closed
39,307
|
$7,139,723,000 | |
| Natera Inc |
Closed
125,043
|
$6,942,387,000 | |
| AnaptysBio Inc |
Opened
256,307
|
$6,423,053,000 | 0.87% |
| Crinetics Pharmaceuticals In |
Opened
141,375
|
$6,332,186,000 | 0.86% |
| Arcus Biosciences Inc |
303.48%
415,535
|
$6,328,598,000 | 0.86% |
| Haemonetics Corp Mass |
45.94%
76,079
|
$6,294,016,000 | 0.86% |
| Madrigal Pharmaceuticals Inc |
Closed
25,840
|
$6,259,998,000 | |
| Evolent Health Inc |
Closed
186,923
|
$6,065,651,000 | |
| Castle Biosciences, Inc. |
Opened
277,895
|
$6,049,774,000 | 0.82% |
| Teva Pharmaceutical Inds Ltd |
Opened
353,942
|
$5,751,558,000 | 0.78% |
| Ironwood Pharmaceuticals Inc |
Opened
876,268
|
$5,713,267,000 | 0.78% |
| Silence Therapeutics plc |
82.55%
289,841
|
$5,506,979,000 | 0.75% |
| Insmed Inc |
Opened
80,271
|
$5,378,157,000 | 0.73% |
| Cvrx Inc |
Opened
447,620
|
$5,366,964,000 | 0.73% |
| Applied Therapeutics, Inc. |
Opened
1,148,307
|
$5,362,594,000 | 0.73% |
| Avadel Pharmaceuticals plc |
Opened
378,289
|
$5,318,743,000 | 0.72% |
| Sutro Biopharma Inc |
62.97%
1,792,740
|
$5,252,728,000 | 0.72% |
| Amicus Therapeutics Inc |
Opened
502,463
|
$4,984,433,000 | 0.68% |
| Biogen Inc |
Closed
17,920
|
$4,982,298,000 | |
| Supernus Pharmaceuticals Inc |
Closed
131,878
|
$4,777,940,000 | |
| Replimune Group Inc |
Opened
525,000
|
$4,725,000,000 | 0.64% |
| Performant Finl Corp |
4.46%
1,623,199
|
$4,707,277,000 | 0.64% |
| LivaNova PLC |
Opened
85,159
|
$4,668,416,000 | 0.64% |
| UroGen Pharma Ltd |
Opened
274,465
|
$4,605,523,000 | 0.63% |
| Veracyte Inc |
76.59%
209,475
|
$4,539,323,000 | 0.62% |
| Moonlake Immunotherapeutics |
Opened
101,224
|
$4,450,819,000 | 0.61% |
| Avid Bioservices Inc |
36.82%
621,091
|
$4,434,590,000 | 0.60% |
| Ultragenyx Pharmaceutical In |
Opened
100,000
|
$4,110,000,000 | 0.56% |
| ANI Pharmaceuticals Inc |
Closed
100,000
|
$3,972,000,000 | |
| Danaher Corp. |
Closed
15,216
|
$3,835,041,000 | |
| 89bio Inc |
Closed
246,956
|
$3,761,140,000 | |
| Waters Corp. |
Closed
11,867
|
$3,674,379,000 | |
| KORU Medical Systems Inc |
Closed
851,375
|
$3,592,803,000 | |
| Fortrea Hldgs Inc |
Opened
152,769
|
$3,565,628,000 | 0.49% |
| Arvinas Inc |
Opened
125,161
|
$3,331,786,000 | 0.45% |
| Nuvalent Inc |
Opened
42,888
|
$3,253,484,000 | 0.44% |
| TG Therapeutics Inc |
34.58%
180,320
|
$3,207,893,000 | 0.44% |
| Immunovant Inc |
Closed
186,045
|
$2,885,558,000 | |
| Kiniksa Pharmaceuticals International Plc. |
Closed
250,257
|
$2,692,765,000 | |
| Ventyx Biosciences Inc |
Opened
1,160,022
|
$2,679,651,000 | 0.36% |
| Merus N.V |
Opened
45,152
|
$2,671,644,000 | 0.36% |
| Terns Pharmaceuticals Inc |
420.36%
390,270
|
$2,657,739,000 | 0.36% |
| Newamsterdam Pharma Company |
17.72%
135,376
|
$2,600,573,000 | 0.35% |
| Esperion Therapeutics Inc Ne |
39.08%
1,144,646
|
$2,541,114,000 | 0.35% |
| Biocryst Pharmaceuticals Inc. |
Opened
400,448
|
$2,474,769,000 | 0.34% |
| Dynavax Technologies Corp. |
Opened
216,822
|
$2,434,911,000 | 0.33% |
| IVERIC bio Inc |
Closed
97,082
|
$2,362,005,000 | |
| Quanterix Corp |
Opened
176,377
|
$2,329,940,000 | 0.32% |
| Legend Biotech Corp |
Closed
47,608
|
$2,295,658,000 | |
| Liquidia Corp |
Closed
326,965
|
$2,259,328,000 | |
| Axogen Inc. |
Closed
223,783
|
$2,114,749,000 | |
| SI-BONE Inc |
Opened
153,015
|
$1,978,484,000 | 0.27% |
| Cogent Biosciences, Inc. |
Closed
181,896
|
$1,962,658,000 | |
| Procept Biorobotics Corp |
Closed
67,252
|
$1,909,957,000 | |
| Elanco Animal Health Inc |
Opened
126,042
|
$1,818,786,000 | 0.25% |
| Cullinan Oncology, LLC |
Closed
169,886
|
$1,737,934,000 | |
| Third Harmonic Bio Inc |
Opened
133,325
|
$1,733,225,000 | 0.24% |
| Marinus Pharmaceuticals Inc |
Closed
250,000
|
$1,725,000,000 | |
| Establishment Labs Holdings Inc |
Closed
25,000
|
$1,693,500,000 | |
| Apellis Pharmaceuticals Inc |
Closed
25,000
|
$1,649,000,000 | |
| Lexicon Pharmaceuticals Inc |
Closed
675,328
|
$1,641,047,000 | |
| Annexon Inc |
Opened
326,845
|
$1,601,541,000 | 0.22% |
| Mirum Pharmaceuticals Inc |
Closed
62,118
|
$1,492,074,000 | |
| Galera Therapeutics Inc |
Closed
525,000
|
$1,344,000,000 | |
| Aclaris Therapeutics Inc |
Closed
166,020
|
$1,343,102,000 | |
| Essa Pharma Inc |
Opened
252,072
|
$1,325,899,000 | 0.18% |
| Ardelyx Inc |
Opened
150,192
|
$1,112,923,000 | 0.15% |
| Viking Therapeutics Inc |
Opened
20,372
|
$1,079,920,000 | 0.15% |
| Sage Therapeutics Inc |
Closed
25,321
|
$1,062,469,000 | |
| Akoya Biosciences Inc |
86.48%
375,536
|
$878,754,000 | 0.12% |
| Eton Pharmaceuticals, Inc. |
Opened
253,197
|
$833,018,000 | 0.11% |
| Cidara Therapeutics Inc |
Closed
600,000
|
$762,000,000 | |
| Entera Bio Ltd |
Opened
401,518
|
$738,793,000 | 0.10% |
| Inozyme Pharma, Inc. |
Closed
125,000
|
$716,250,000 | |
| Immunic, Inc. |
Closed
459,770
|
$685,057,000 | |
| VYNE Therapeutics Inc. |
Opened
345,206
|
$680,056,000 | 0.09% |
| Reviva Pharmaceutcls Hldgs I |
Opened
504,600
|
$645,888,000 | 0.09% |
| Aadi Bioscience Inc |
Closed
75,961
|
$549,958,000 | |
| Augmedix Inc |
Opened
566,845
|
$498,824,000 | 0.07% |
| Acutus Med Inc |
Closed
653,721
|
$492,906,000 | |
| X4 Pharmaceuticals, Inc. |
71.16%
806,616
|
$467,837,000 | 0.06% |
| TELA Bio, Inc. |
28.79%
97,816
|
$459,735,000 | 0.06% |
| Gritstone Bio Inc |
Closed
151,921
|
$422,340,000 | |
| Alpha Teknova Inc |
96.13%
296,652
|
$406,413,000 | 0.06% |
| Savara Inc |
Closed
177,243
|
$345,624,000 | |
| Xeris Biopharma Holdings Inc |
Opened
100,830
|
$226,868,000 | 0.03% |
| Mineralys Therapeutics Inc |
Closed
10,000
|
$156,600,000 | |
| No transactions found | |||
| Showing first 500 out of 134 holdings | |||
Hedge funds similar to Parkman Healthcare Partners
- Private Advisory
- Portland Global Advisors
- Quest Partners
- Robotti Robert
- Oribel Capital Management, L.P.
- North American Management Corp
- Covalis Capital LL.P.
- Cutler Investment Counsel
- Gamma Investing
- Cahill Financial Advisors Inc
- Lvz
- Clean Transition LL.P.
- Alley Investment Management
- Institute For Wealth Management,